INCY Stock: Incyte Corporation Stock Price, Analysis & Insights
Get live INCY stock price $97.16, comprehensive Incyte Corporation stock analysis, charts, news, and expert forecast. Real-time INCY stock data and investment insights.
Loading chart data...
Incyte Corporation (INCY) Overview
Incyte Corporation (INCY) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, INCY trades at $97.16 with a market capitalization of 19.41B . Over the past 52 weeks, INCY has traded between $63.93 and $112.29 , with the current price positioned at approximately 69% of this range . The stock currently trades at...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 19.41B
- Current price: $97.16
- 52-week range: $63.93 - $112.29
- P/E ratio: 13.72
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis a...
Company Information
- CEO
- William J. Meury
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2617
Contact Information
- Website
- https://www.incyte.com
- Address
- 1801 Augustine Cut-Off
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 13.7)
✓ Lower volatility stock (Beta: 0.80) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Incyte Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Incyte Corporation
- ⚠Investors should consider how Incyte Corporation fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
19.41B
P/E Ratio (TTM)
13.72
Beta
0.80
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Healthcare Stocks
Compare INCY with:
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.